Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters  by Raef, Hussein et al.
International Journal of Diabetes Mellitus 1 (2009) 2–6Contents lists available at ScienceDirect
International Journal of Diabetes Mellitus
journal homepage: ees .e lsevier .com/ locate/ i jdmOriginal Article
Adding rosiglitazone to metformin in patients with type 2 diabetes:
Effect on diabetes control and metabolic parameters
Hussein Raef a,*, Abdulraof Al-Mahfouz a, Abdullah Al-Khonaizan b
aDepartment of Medicine (MBC-46), King Faisal Specialist Hospital and Research Center (KFSH & RC), P.O. Box 3354, Riyadh 11211, Saudi Arabia
bDepartment of Family Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabiaa r t i c l e i n f o
Article history:
Received 21 July 2008




Type 2 diabetes mellitus1877-5934/ 2009 International Journal of Diabetes M
doi:10.1016/j.ijdm.2009.03.001
* Corresponding author. Tel.: +966 1 442 7490; fax
E-mail address: hraef@kfshrc.edu.sa (H. Raef).a b s t r a c t
Aim: To evaluate the efﬁcacy and tolerability, any changes in lipid parameters including free fatty acids
and effect on weight and blood pressure, of adding Rosiglitazone to patients with type 2 DM who are not
adequately controlled on maintenance dose of Metformin.
Methods: Prospective study of 14 patients with type 2 DM who were maintained on Metformin alone
(1.5–2.5 g/day). Twelve patients met the inclusion criteria, and received 4 mg of Rosiglitazone daily in
addition to Metformin. Patients were followed for 24 weeks and seen for 6–7 visits. The dose of Rosiglit-
azone was increased after 8 weeks if FBG was stillP160 mg/dl. Full biochemical evaluation was done and
safety parameters were observed at base line, at intervals during the study and at the end of the study. All
patients completed the study. T test was used for comparison.
Results: Eight males and four females were studied. They had the following characteristics: Mean age was
(52 ± 6.9) years, weight was (78.2 ± 10.1) kg BMI was (28 ± 4) kg/m2, waist circumference was
(97.5 ± 6.5) cm, and duration of DM was (7.3 ± 6) years. Four patients required an increase of Rosiglitaz-
one dose to 8 mg after 8 weeks.
All patients showed improvement of HbA1c levels by the end of the study. When mean base line
parameters were compared to those at the end of study: HbA1c level dropped from (8.9% ± 1.5) to
(7.1% ± 1.1) (P: 0.00003) and FBG from (205 ± 50.6) to (150 ± 28) mg/dl (P: 0.002). Free Fatty Acids
(FFA) dropped from (703 ± 213) to (510 ± 303.6) by 8 weeks and to (574 ± 184.6) leq/L by the end of
the study, (P: 0.01 and 0.06, respectively). Improvement in HbA1c did not however correlate with the
level of FFA drop. There was also signiﬁcant increase in HDL level (1.15 ± 0.14)–(1.27 ± 0.2) mmol/L, (P:
0.02), and weight (78.2 ± 10.1)–(80.1± 10.9) kg (P: 0.01). The changes in LDL (3.02 ± 0.57)–
(3.23 ± 0.5) mmol/L, TG (2.16 ± 1.1)–(2.2 ± 1.33) mmol/L, waist circumference (97.5 ± 6.5)–(99 ± 8.1) cm,
and BP (132.5 ± 17)–(130.2 ± 18.8) mm Hg (systolic), were not signiﬁcant.
When ‘‘Good Responders”, (HbA1c drop of >1.5%), (nine subjects) were compared to those with less
than 1.5% drop (three subjects), there were no speciﬁc characteristics to deﬁne responders.
Conclusion: Rosiglitazone, added to Metformin in type 2 DM patients, was effective and well tolerated.
There was a signiﬁcant decrease in FFA levels with treatment. The response to treatment, however could
not be predicted from biochemical or clinical parameters. A larger study may be needed to deﬁne respon-
der characteristics.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction Most type 2 DM patients however, would require an addition ofThe use of an insulin sensitizer as a ﬁrst line oral agent in the
treatment of type 2 diabetes mellitus (T2DM) is widely accepted
and may have an advantage over the use of an insulin
secretagouge.
Metformin has been frequently advocated as a ﬁrst line agent,
especially in obese type 2 DM patients with mild to moderate
hyperglycemia. The safety of Metformin has been well established
[1].ellitus. Published by Elsevier Ltd. O
: +966 1 442 4771.a second and frequently a third agent with the progression of their
DM [2]. Eventually many patients with type 2 DM would require
insulin during the course of their disease [3].
Patients who present with moderate to severe hyperglycemia
may require two oral agents or insulin at the onset. Using two oral
hypoglycemic agents of different classes of actions simultaneously
as a ﬁrst line treatment of type 2 DM has also been considered
recently for better and more efﬁcient control with fewer side ef-
fects [4].
Thiozolidinediones is a group of relatively recent oral hypogly-
cemic drugs with novel mechanism of action. Although the exact
mechanisms of action for those drugs are still being investigated,pen access under CC BY-NC-ND license.
H. Raef et al. / International Journal of Diabetes Mellitus 1 (2009) 2–6 3they seem to work primarily by stimulating the nuclear receptor
PPAR gamma which mediates or affects carbohydrate metabolism.
The effect on the PPAR alpha that alters lipid metabolism is less
pronounced. They can also decrease peripheral resistance and
improve glucose uptake especially in muscle and adipose tissue
[5]. These agents can also decrease gluconeogenesis by improving
liver insulin sensitivity [6]. Some of the Thiozolidinediones actions
may be mediated by a decrease in free fatty acid level [7].
The efﬁcacy of Thiozolidinediones was shown in number of
studies as single agents [8], or in combination with Metformin or
Sulfonyureas [9–11]. Regional, smaller size studies were also con-
ducted in some countries and found Rosiglitazone to be beneﬁcial
in patients with type 2 diabetes who were not controlled on a com-
bination of Sulfonylurea and Metformin [26], or when added with
sulfonylurea and Metformin to type 2 patients who were not well
controlled on insulin [27].
The speciﬁc advantage of these drugs over others are emerging
with the ability to preserve and improve b cell function. Although
the long term clinical effects of Glitazones on cardiovascular risk in
patients with diabetes have not yet been proved, studies did show
signiﬁcant improvement in markers such as Adiponectin and a
decrease in inﬂammatory markers like C Reactive Protein (CRP),
Tumor Necrosis Factor (TNF) and Resistin [12]. In the PRO active
study, pioglitazone was shown to signiﬁcantly reduce the compos-
ite of all causes of mortality, non-fatal myocardial infarction, and
stroke (secondary end point) in high risk type 2 DM patients [13].MORE ABOUT THIS STUDY
Free fatty acids and other metabolic parameters were moni-
tored throughout the study.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC
Rosiglitazone was shown to be effective and relatively safe
when added to other oral agents like Metformin in type 2
DM patients. Recent but still controversial data, however,
cautions a possible increase in cardiovascular events in pa-
tients taking Rosiglitazone.
WHAT THIS STUDY ADDS
The efficacy and relative safety of adding Rosiglitazone to
Merfomin in type 2 DM patients were tested in local
population.
The study confirms the efficacy & the relative safety of the
addition of Rosiglitazone to Metformin in this group of type 2
DM patients. The drop in free fatty acids did not correlate with
response, which might argue for additional mechanisms of
action.
These agents however are not without side effects, most notably
mild to moderate weight gain, due to water retention especially if
combined with insulin (Rosiglitazone not indicated for such com-
bination) or due to redistribution of body fat [14]. Decreased bone
density [25] and an increased incidence of heart failure were also
reported with rosiglitazone [22–24].
In a recent meta-analysis of two large and a few smaller studies
using Rosiglitazone, authors found an increase in the risk of myo-
cardial infarction associated with treatment with rosiglitazone
[22]. Interim analysis of another trial (RECORD) also found a small,
though non-signiﬁcant increase in the risk of cardiovascular events
(composite of hospitalization and death from cardiovascular
causes) [23,24]. More careful post marketing studies are therefore
needed to address this new issue.
A study on the use of Rosiglitazone in patients with type 2 DM
taking Metformin was performed previously [10,11], and indicated
that the combination of Rosiglitazone and Metformin is safe and
effective.This study was thus conducted to examine the effect and safety
of this combination in a local population (part of multicenter inter-
national protocol in Middle Eastern and North African countries).
We have analyzed the data on patients studied at our center.
2. Patients and methods
Patients aged between 40 and 80 years with type 2 DM (accord-
ing to American Diabetes Association (ADA) criteria), for at least 3
month, who had been on Metformin (1.5–2.5 g/D) for at least 3
month before enrollment in the study, but not adequately con-
trolled, were recruited from the family clinics of the King Faisal
Specialist Hospital & Research Center. Patients with pregnancy,
major medical problems, heart failure, liver or renal dysfunction,
elevated creatinine, more than 133 lmol/L for male or 124 lmol/
L for female or ALT, AST, or Alk Phosphatase higher than 2.5 times
the upper normal limit, were excluded. Women at reproductive
age had to be on contraceptives. Fourteen patients who were on
Metformin alone were identiﬁed and screened for the study after
taking their consent. All patients had screening visit with full clin-
ical evaluation, medication history, physical examination, and
chemistry labs with urine HCG if indicated and base line ECG.
Patients dietary habits were evaluated and basic dietary
instructions were provided by a dietician, only if needed. Most of
the patients were fairly active though they did not take exercise
regularly. No recommendations were made for any change in the
level of activity during the study period. Laboratory tests included
full chemistry proﬁle (including CBC, electrolytes, renal, and hepa-
tic function tests), Fasting Blood Glucose (FBG), lipid proﬁle, urine
analysis and free fatty acid levels. All biochemical studies were
done at our laboratory using automated Roche Modular P 800.
The free fatty acid levels were determined at the Mayo clinic labo-
ratory (Rochester, Minnesota) using enzymatic colorimetric assay.
At the base line visit, which was 2 weeks after the screening visit,
Laboratory tests were repeated and patients received 4 mg of Ros-
iglitazone daily in addition to their usual dose of Metformin, if FBG
was equal or more than 140 mg/dl but less than 300 mg/dl and
others were excluded. Twelve patients met the inclusion criteria.
Patients were followed for 24 weeks and seen for 6–7 visits. The
dose of Rosiglitazone was increased after 8 weeks (visit 4) if FBG
was still P160 mg/dl. Full biochemical evaluation and safety
parameters were done at screening visit, base line visit, visit 4,
and at the end of the study. Clinical evaluation, evaluation of side
effects, vital signs, waist measurements and fasting glucose were
done in all visits. All patients remained on their usual medications
during the study. All patients completed the study. Good respond-
ers were deﬁned as those with Glycosylated (HbA1c) drop of
P1.5%. T test was used for comparison. The study was approved
by the medical research council and the ethics committee of our
center.3. Results
All patients (eight male and four female) completed the study.
The patient characteristics at base line are summarized in Table 1.
When mean base line parameters of patients were compared to
those at the end of study; HbA1c level dropped from 8.9% ± 1.5 to
7.1% ± 1.1 (P: 0.00003), and FBG from 205 ± 51.6 to 150 ± 28 mg/dl
(P: 0.002). FFA dropped from 703 ± 213 to 510 ± 303.6 leq/L by 8
weeks and to 574 ± 184.6 leq/L by the end of the study, (P: 0.01
and 0.06, respectively) (Figs. 1–3).
There was no correlation, however, between the improvement
in HbA1c and the level of FFA drop. Four patients required an in-
crease of Rosiglitazone dose to 8 mg at week 8 of the study, be-
cause FBG was higher than 160 mg/dl.
Table 1
Characteristics of the 12 patients in the study at base line, mean with standard
deviation and (range).
Age (years) 52 ± 6.9 (44–67)
Weight (kg) 78.2 ± 10.1 (64–95)
BMI (kg/m2) 28 ± 4 (22.7–35.5)
Waist diameter (cm) 97.5 ± 6.5 (87–109)
Duration of DM (years) 7.3 ± 6 (1–20)
Fig. 1. Mean HbA1C level of patients at base line and at the end of the study.
Fig. 2. Mean FBG level for all patients at base line and at the end of the study.
Fig. 3. Mean free fatty acid levels (leq/L) for all patients at base line, 8 weeks and at
the end of the study.
Fig. 4. Mean LDL, HDL, and TG levels for all patients at base line and at the end of
the study, there were no signiﬁcant changes in LDL and TG levels, but a signiﬁcant
increase in HDL.
Fig. 5. Mean weight, BMI and waist diameter for all patients at base line and at the
end of the study, there was mild but signiﬁcant gain of weight and increase in BMI
at the end of the study, but no signiﬁcant change in waist diameter.
Fig. 6. Mean systolic and diastolic BPs at base line and at the end of the study. There
was no signiﬁcant change in BPs.
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the study (range 0.2–3%). Two patients had a drop of HbA1c levels
of less than 1 (0.2% and 0.4%) and one patient had a drop of 1.3%,
while nine patients had a drop of more than 1.5%.
There was also a signiﬁcant increase in High Density Lipopro-
tein (HDL) levels, and a mild but signiﬁcant increase in weight after
treatment. Low Density Lipoprotein (LDL), Triglyceride (TG), waist
circumference, and Blood Pressure (BP) did not show signiﬁcant
changes (Figs. 4–6).
When ‘‘Good Responders” (nine subjects) were compared to
those with less than a 1.5% drop in HbA1c (three subjects), there
were no speciﬁc characteristics to deﬁne responders, although‘‘Good responders” tended to have lower FFA levels at base line
(P: 0.06), and to have higher Body Mass Index (BMI) and HbA1c
at base line (Table 2).
4. Discussion
Insulin resistance and impairment in insulin secretion are
important factors in the pathophysiology of type 2 DM. The
Table 2
Comparison of the characteristics of better responders (HbA1c drop of P1.5%) and
those with less response.
Good responders Others P value
Base line (weight) 79.1 75.3 0.2
Base line BMI (kg/m2) 28.6 26.3 0.1
Age (years) 52.4 50.6 0.3
DM duration (years) 8 5.3 0.2
Base line FBG (mg/dl) 196 231 0.2
Base line HbA1c (%) 9.1 8.4 0.2
Base line FFA (leq/L) 628 926 0.06
End of study FFA (leq/L) 589 529 0.2
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even during the natural progression of the disease in the same
patient [28,29].
The advantages of using oral agents that are primarily insulin
sensitizers over those that are insulin secretagouges are lower
blood insulin levels and less or no hypoglycemia [30]. The effects
of insulin secretagouges also wane with time due to decreasing
ability of these agents to stimulate insulin secretions from b cell.
The use of Rosiglitazone was associated with less failure as
mono-therapy than Metformin and Glyburide in a recent large trial
(ADOPT) [19]. Another trial (DREAM) found Rosiglitazone to be
effective in reversing those with mild early diabetes to a pre-dia-
betic stage [20,21].
The combination of Thiozolidendione and Metformin as an ini-
tial or sequential treatment of type 2 DMmay have signiﬁcant clin-
ical advantages. The two agents work in two different mechanisms
of decreasing peripheral resistance at the muscle level and in
decreasing hepatic glucose output respectively. Both of them do
not induce hypoglycemia or increase insulin secretion. The pres-
ence of Glitazone has the advantage of preserving endogenous
insulin secretion for a longer period as compared to those on
secretagogues [8]. Side effects may be less with smaller doses of
Glitazones in combinations with Metformin, especially in terms
of weight gain. In one study, the addition of Rosiglitazone was
found to result in better control than an escalating Metformin dose
in type 2 DM patients with suboptimal control on Metformin alone
[15]. Our results indicated a good efﬁcacy for the drug in our pa-
tients, with 10 patients out of 12 having more than a 1% drop in
their HbA1c levels, and 9 with 1.5 points or more drop. These re-
sults are comparable or better than generally published interna-
tional data [9–11]. There are number of possibilities to account
for this success in our patients: First; the average HbA1c level at
base line is rather high which indicates a worse control at base line
than generally reported in similar studies, which can result in a
sharper drop of HbA1c levels to the additional treatment. Second,
the patients were followed closely, and might have become more
motivated to achieve better control. However, it is equally feasible
that Glitazones exert better effect on certain patients than others,
and that we had a larger proportion of good responders in the
group studied. We attempted to identify the characteristics of good
responders by comparing those with an improved HbA1c of 1.5% or
more, to others with less than 1.5% drop. There were no signiﬁcant
differences between the two groups. The number of patients, espe-
cially those with less response, was however too small for mean-
ingful comparison. Nevertheless, it was noted that the base line
FFA was lower in the better responders (p = 0.06). This may indi-
cate less insulin resistance in this group.
It is interesting to note that the level of response did not corre-
late with the drop of free fatty acid levels, in spite of a signiﬁcant
decrease in its level, especially after 8 weeks of treatment.
The small number of patients in this study, and the heterogene-
ity of patient responses, might account for this lack of correlation.
Other mechanisms of action may also be responsible for the Rosig-litazone effect, such as the effects on beta-cell function and insulin
sensitivity [5–7].
In the ‘‘A Diabetes Outcome Progression Trial” (ADOPT) study,
Rosiglitazone was found to be more effective than both Glibencla-
mide and Metformin in sustaining glycaemic control in the long-
term with the greatest response observed in older patients (>50
years) and those with a higher base line BMI (>30) and larger waist
circumference (>110 cm) [19], a trend that we saw in our studied
patients.
Our patients also tolerated the treatment well. There were no
major side effects attributed to the addition of Rosiglitazone in
our patients, and the drug was not discontinued in any of our 12
patients. In one of the patients with underlying mild valvular heart
disease and history of bronchial asthma, an increase in shortness of
breath occurred for a period after increasing the dose of Rosiglitaz-
one to 8 mg. In this patient, investigations pointed to asthma exac-
erbation and symptoms resolved after a short period without
changing the dose of Rosiglitazone. Nevertheless, there was mild
to moderate weight gain in most of the patients, with a mean in-
crease of 1.9 kg (range 1.5 to 5.8 kg). Weight gain is reported to
occur with all Thiozolidinedione agents, but seems to be less when
these agents are combined with Metformin [10,11]. Weight gain is
usually attributed to mild water retention (more when these
agents are used with insulin) and to fat tissue redistribution from
central to peripheral sites. Improvement of DM control can also be
associated with some increase in weight [31]. In our patients, there
was no correlation between the degree of weight gain and the re-
sponse to treatment. The better responders gained 1.7 kg on aver-
age, whereas the poor responders gained 2.6 kg on average.
Rosiglitazone can be associated with mild increase in total cho-
lesterol, LDL and TG [11,16]. In this study, however, there were no
signiﬁcant changes in LDL or TG levels. It is of interest that there
was a small but signiﬁcant increase in HDL levels in our patients.
Others have also reported favorable effects on lipids and inﬂamma-
tory markers [16]. We also observed no change in BP in our pa-
tients. Other reports also showed little or no change in blood
pressure or even a decrease after the use of Glitazones [17,18].
There were no signiﬁcant changes in liver enzymes in our pa-
tients, which is in agreement with other studies on Rosiglitazone
and Pioglitazone [10,11].
In summary, we believe that our study, though limited by its
small size, supports larger randomized controlled studies in show-
ing the advantage and relative safety of the addition of Rosiglitaz-
one to Metformin in patients with type 2 DM who are not well
controlled on Metformin alone. It is reasonable, however, consider-
ing the short duration of our study and the recent data on potential
cardiovascular risks [23,24], to use judgment and caution when
monitoring therapy with Rosiglitazone in a patient with high car-
diovascular risk.
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